These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
136 related items for PubMed ID: 23494860
21. Effects of bisphosphonate treatment on bone repair under immunosuppression using cyclosporine A in adult rats. Matsunaga T, Shigetomi M, Hashimoto T, Suzuki H, Gondo T, Tanaka H, Sugiyama T, Taguchi T. Osteoporos Int; 2007 Nov; 18(11):1531-40. PubMed ID: 17492246 [Abstract] [Full Text] [Related]
22. Does zoledronate therapy make mandibular bone susceptible to fracture? A radiographical and biomechanical study in rats. Zandi M, Shokri A, Mousavi M, Rajaei S, Mohammad Gholi Mezerji N. Injury; 2018 Oct; 49(10):1746-1749. PubMed ID: 30007517 [Abstract] [Full Text] [Related]
23. Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. Little DG, Peat RA, Mcevoy A, Williams PR, Smith EJ, Baldock PA. J Bone Miner Res; 2003 Nov; 18(11):2016-22. PubMed ID: 14606515 [Abstract] [Full Text] [Related]
24. Effects of zoledronate on markers of bone metabolism and subchondral bone mineral density in dogs with experimentally induced cruciate-deficient osteoarthritis. Agnello KA, Trumble TN, Chambers JN, Seewald W, Budsberg SC. Am J Vet Res; 2005 Sep; 66(9):1487-95. PubMed ID: 16261820 [Abstract] [Full Text] [Related]
25. Effects of zoledronate on irradiated bone in vivo: analysis of the collagen types I, V and their cross-links lysylpyridinoline, hydroxylysylpyridinoline and hydroxyproline. Açil Y, Gierloff M, Behrens C, Möller B, Gassling V, Niehoff P, Wiltfang J, Simon M. Calcif Tissue Int; 2013 Mar; 92(3):251-60. PubMed ID: 23179106 [Abstract] [Full Text] [Related]
26. A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats. Gasser JA, Green JR, Shen V, Ingold P, Rebmann A, Bhatnagar AS, Evans DB. Bone; 2006 Oct; 39(4):787-95. PubMed ID: 16844441 [Abstract] [Full Text] [Related]
27. Evaluation of mandibular fracture healing in rats under zoledronate therapy: A histologic study. Zandi M, Dehghan A, Amini P, Rezaeian L, Doulati S. Injury; 2017 Dec; 48(12):2683-2687. PubMed ID: 29042034 [Abstract] [Full Text] [Related]
28. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment. Kimoto A, Tanaka M, Nozaki K, Mori M, Fukushima S, Mori H, Shiroya T, Nakamura T. Bone; 2013 Jul; 55(1):189-97. PubMed ID: 23486179 [Abstract] [Full Text] [Related]
29. Does exercise modify the effects of zoledronic acid on bone mass, microarchitecture, biomechanics, and turnover in ovariectomized rats? Lespessailles E, Jaffré C, Beaupied H, Nanyan P, Dolléans E, Benhamou CL, Courteix D. Calcif Tissue Int; 2009 Aug; 85(2):146-57. PubMed ID: 19609736 [Abstract] [Full Text] [Related]
30. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice. Liu J, Xu K, Wen G, Guo H, Li S, Wu X, Dai R, Sheng Z, Liao E. Bone; 2008 May; 42(5):950-9. PubMed ID: 18337202 [Abstract] [Full Text] [Related]
31. Augmentation of autologous bone graft by a combination of bone morphogenic protein and bisphosphonate increased both callus volume and strength. Bosemark P, Isaksson H, McDonald MM, Little DG, Tägil M. Acta Orthop; 2013 Feb; 84(1):106-11. PubMed ID: 23409846 [Abstract] [Full Text] [Related]
32. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA. Xu XJ, Ma DD, Lv F, Wang JY, Liu Y, Xia WB, Jiang Y, Wang O, Xing XP, Yu W, Li M. Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615 [Abstract] [Full Text] [Related]
33. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment. Allen MR, Reinwald S, Burr DB. Calcif Tissue Int; 2008 May; 82(5):354-60. PubMed ID: 18463913 [Abstract] [Full Text] [Related]
34. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. Allen MR, Burr DB. J Bone Miner Res; 2007 Nov; 22(11):1759-65. PubMed ID: 17663638 [Abstract] [Full Text] [Related]
35. Zoledronate and Raloxifene combination therapy enhances material and mechanical properties of diseased mouse bone. Powell KM, Skaggs C, Pulliam A, Berman A, Allen MR, Wallace JM. Bone; 2019 Oct; 127():199-206. PubMed ID: 31233931 [Abstract] [Full Text] [Related]
37. Prevention of strain-related osteopenia in aseptic loosening of hip prostheses using perioperative bisphosphonate. Goodship AE, Blunn GW, Green J, Coathup MJ. J Orthop Res; 2008 May; 26(5):693-703. PubMed ID: 18050308 [Abstract] [Full Text] [Related]
38. Systemic zoledronate precoating of a bone graft reduces bone resorption during remodeling. Tägil M, Aspenberg P, Astrand J. Acta Orthop; 2006 Feb; 77(1):23-6. PubMed ID: 16534698 [Abstract] [Full Text] [Related]
39. Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. Little DG, McDonald M, Bransford R, Godfrey CB, Amanat N. J Bone Miner Res; 2005 Nov; 20(11):2044-52. PubMed ID: 16234978 [Abstract] [Full Text] [Related]
40. Zoledronate inhibits ischemia-induced neovascularization by impairing the mobilization and function of endothelial progenitor cells. Tsai SH, Huang PH, Chang WC, Tsai HY, Lin CP, Leu HB, Wu TC, Chen JW, Lin SJ. PLoS One; 2012 Nov; 7(7):e41065. PubMed ID: 22848429 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]